- cafead Aug 30, 2021 at 11:02: AM
via Close to 3 years after tiny Belgian biotech Bone Therapeutics crashed on the Phase III failure of its treatment for osteonecrosis, it’s back with another pivotal flop.
This time the Phase III failure is for their “viscosupplement” JTA-004 for osteoarthritis, which went down on the primary and both secondary endpoints. The primary endpoint was a reduction in knee pain at 3 months compared against a placebo.
article source
This time the Phase III failure is for their “viscosupplement” JTA-004 for osteoarthritis, which went down on the primary and both secondary endpoints. The primary endpoint was a reduction in knee pain at 3 months compared against a placebo.
article source